PA

Your Article Summary

Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States
Annals of Internal Medicine, 10/20/09

Kim JJ et al. – This analysis assessed the cost–effectiveness of HPV vaccination for women aged 35 to 45 years. It found that vaccination ranged from $116 950 to $381 590 per quality–adjusted life–year gained across various assumptions about how clinicians would screen for cervical cancer and HPV infection in addition to vaccination. Given currently available information, the effectiveness of HPV vaccination for women older than 30 years who are screened seems to be small. Compared with current screening that uses sensitive HPV DNA testing, HPV vaccination is associated with less attractive cost–effectiveness ratios in this population than those for other, well–accepted interventions in the United States.